NSN Co. Ltd
DHX Company Co., Ltd. engages in biomedical and distribution businesses in South Korea. The company offers Microbiome to treat intractable skin diseases; REJURUB; and AI digital brain diagnostic device. It also purchases and distributes IT components, including graphics cards, DRAM, CPUs, high-capacity storage, and multi-purpose displays; import and distribution of cosmetics; f and b distribution… Read more
NSN Co. Ltd - Asset Resilience Ratio
NSN Co. Ltd (031860) has an Asset Resilience Ratio of 1.72% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2024)
This chart shows how NSN Co. Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down NSN Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.05 Billion | 1.72% |
| Total Liquid Assets | ₩1.05 Billion | 1.72% |
Asset Resilience Insights
- Limited Liquidity: NSN Co. Ltd maintains only 1.72% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
NSN Co. Ltd Industry Peers by Asset Resilience Ratio
Compare NSN Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
|
Bionet
TWO:1784 |
Diagnostics & Research | 38.62% |
Annual Asset Resilience Ratio for NSN Co. Ltd (2006–2024)
The table below shows the annual Asset Resilience Ratio data for NSN Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 18.29% | ₩10.27 Billion | ₩56.16 Billion | +0.80pp |
| 2023-12-31 | 17.49% | ₩11.56 Billion | ₩66.08 Billion | +11.00pp |
| 2022-12-31 | 6.49% | ₩5.38 Billion | ₩82.93 Billion | -12.03pp |
| 2021-12-31 | 18.52% | ₩12.02 Billion | ₩64.91 Billion | -8.54pp |
| 2020-12-31 | 27.06% | ₩16.57 Billion | ₩61.22 Billion | -29.13pp |
| 2019-12-31 | 56.19% | ₩38.40 Billion | ₩68.33 Billion | +51.91pp |
| 2018-12-31 | 4.28% | ₩1.31 Billion | ₩30.67 Billion | +0.75pp |
| 2017-12-31 | 3.53% | ₩1.15 Billion | ₩32.56 Billion | -0.67pp |
| 2016-12-31 | 4.19% | ₩1.91 Billion | ₩45.47 Billion | +1.13pp |
| 2015-12-31 | 3.06% | ₩1.20 Billion | ₩39.20 Billion | +1.60pp |
| 2014-12-31 | 1.46% | ₩555.73 Million | ₩38.09 Billion | -0.24pp |
| 2013-12-31 | 1.70% | ₩601.75 Million | ₩35.50 Billion | -6.60pp |
| 2012-12-31 | 8.29% | ₩16.28 Billion | ₩196.25 Billion | +1.21pp |
| 2011-12-31 | 7.08% | ₩12.12 Billion | ₩171.11 Billion | -7.55pp |
| 2010-12-31 | 14.63% | ₩21.95 Billion | ₩150.00 Billion | +3.47pp |
| 2006-12-31 | 11.17% | ₩2.59 Billion | ₩23.21 Billion | -- |